658 related articles for article (PubMed ID: 32923140)
1. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
3. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
4. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
5. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
6. How can Cytokine-induced killer cells overcome CAR-T cell limits.
Cappuzzello E; Vigolo E; D'Accardio G; Astori G; Rosato A; Sommaggio R
Front Immunol; 2023; 14():1229540. PubMed ID: 37675107
[TBL] [Abstract][Full Text] [Related]
7. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer.
Wu CC; Pan MR; Shih SL; Shiau JP; Wu CC; Chang SJ; Kao CN; Chen FM; Hou MF; Luo CW
Biomed Pharmacother; 2023 Jul; 163():114732. PubMed ID: 37254289
[TBL] [Abstract][Full Text] [Related]
8. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
9. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
[TBL] [Abstract][Full Text] [Related]
10. Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.
Ren X; Ma W; Lu H; Yuan L; An L; Wang X; Cheng G; Zuo S
Cancer Immunol Immunother; 2015 Dec; 64(12):1517-29. PubMed ID: 26386966
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.
Wei F; Rong XX; Xie RY; Jia LT; Wang HY; Qin YJ; Chen L; Shen HF; Lin XL; Yang J; Yang S; Hao WC; Chen Y; Xiao SJ; Zhou HR; Lin TY; Chen YS; Sun Y; Yao KT; Xiao D
Oncotarget; 2015 Oct; 6(33):35023-39. PubMed ID: 26418951
[TBL] [Abstract][Full Text] [Related]
13. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.
Dalla Pietà A; Cappuzzello E; Palmerini P; Ventura A; Visentin A; Astori G; Chieregato K; Mozzo V; Perbellini O; Tisi MC; Trentin L; Visco C; Ruggeri M; Sommaggio R; Rosato A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272306
[TBL] [Abstract][Full Text] [Related]
14. A CTLA-4 blocking strategy based on Nanoboby in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects.
Wang W; Wang X; Yang W; Zhong K; He N; Li X; Pang Y; Lu Z; Liu A; Lu X
BMC Cancer; 2021 Sep; 21(1):1029. PubMed ID: 34525966
[TBL] [Abstract][Full Text] [Related]
15. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
16. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
17. Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.
Bonanno G; Iudicone P; Mariotti A; Procoli A; Pandolfi A; Fioravanti D; Corallo M; Perillo A; Scambia G; Pierelli L; Rutella S
J Transl Med; 2010 Dec; 8():129. PubMed ID: 21138560
[TBL] [Abstract][Full Text] [Related]
18. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.
Cappuzzello E; Sommaggio R; Zanovello P; Rosato A
Cytokine Growth Factor Rev; 2017 Aug; 36():99-105. PubMed ID: 28629761
[TBL] [Abstract][Full Text] [Related]
19. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
20. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
